Spark Plug Pipe

FN Media Group Presents News Commentary

Once legal cannabis started in several states, companies servicing the industry began to pop up left and right. For example, at the start of 2018 California legalized recreational marijuana and within two weeks, two dozen Los Angeles businesses got approval to sell recreational products. The cannabis industry grows faster than ‘weeds’. The more dispensaries the more demand for products.

So how does one navigate this industry currently? Well the short answer is there are several options. There are ETFs, Canadian Companies, Drug Makers (the medical kind of course) and many more.

Here are a few public companies involved in this booming industry: NightFood Holdings, Inc. (OTC:NGTF), CV Sciences Inc. (OTC:CVSI), GW Pharmaceuticals plc (NASDAQ:GWPH) and Cara Therapeutics, Inc. (NASDAQ:CARA).

NightFood Holdings, Inc. (OTCQB:NGTF)

Market Cap: $11.72M, current share price: $.29

NightFood Holdings, Inc. (NGTF), a brand development company pioneering the projected billion dollar nighttime nutrition category, and developing unique properties and products in the marijuana/cannabis/CBD related snack space, recently announced that the first production run of Half-Baked(TM) branded products has been successfully completed under license in the State of California.

The Half-Baked brand THC-infused cookies each contain 10mg of THC and will retail for approximately $5. As originally announced on April 20, 2018, the product is on track to be available at retail before the end of May.

“This is the birth of a leading national edibles brand in the marijuana space. That’s how we view this initial production run and pilot launch,” commented CEO Sean Folkson. “As more states continue to follow suit and pass marijuana legislation, we see an increase in the value of the opportunity and in the value of the Half-Baked intellectual property.”

CV Sciences, Inc. (OTCQB:CVSI)

Market Cap: $107.48M, current share price: $1.18

CV Sciences, Inc., (CVSI), preeminent manufacturer and distributor of the leading brand of hemp extract products, PlusCBD Oil(TM), announced this week that it will be presenting at the 8th Annual LD Micro Invitational, being held at the Luxe Sunset Boulevard Hotel in Bel-Air, California on June 4-6, 2018.

Joseph Dowling, Chief Financial Officer of CV Sciences, will deliver a corporate presentation covering the Company’s two distinct business segments: its hemp-based CBD products that are distributed to over 1,750 retail stores in the U.S. and #1 in sales in the nutraceuticals hemp CBD market; and its lead drug candidate (CVSI-007) which utilizes synthetically-formulated CBD for use in the treatment of smokeless tobacco addiction. Management will be available for one-on-one meetings with investors.

GW Pharmaceuticals plc (NASDAQ:GWPH)

Market Cap: $4.47 B, current share price: $158.58

GW Pharmaceuticals plc (GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced that The New England Journal of Medicine has published results from a Phase 3 study of cannabidiol oral solution in patients with Lennox-Gastaut syndrome (LGS), a rare, severe and difficult to treat form of childhood-onset epilepsy.1 Cannabidiol oral solution (CBD, Epidiolex®), is a pharmaceutical formulation of highly purified cannabidiol a cannabinoid lacking the high associated with cannabis. In this study, both evaluated doses of cannabidiol oral solution significantly reduced the monthly frequency of drop seizures compared to placebo in highly treatment-resistant patients when added to existing treatment.

Cara Therapeutics, Inc. (NASDAQ:CARA)

Market Cap: $517.91M, current share price: $15.83

Cara Therapeutics, Inc. (CARA), a U.S. biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd (VFMCRP), a joint company of Vifor Pharma Group (VIFN.VX) and Fresenius Medical Care (FMS) that specializes in treatments for CKD. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to KORSUVA injection for this indication, for which there are currently no approved therapies in the U.S. or E.U.

DISCLAIMER: (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Content Provided By: Microcap SpeculatorsEmail: Phone: +1-702-720-6310Website: For Full Legal Disclaimer Click Here .

Media Contact:FN Media Group LLCe-mail: